Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2017-12-01
2019-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients
NCT00872417
Probiotic Supplementation for Those Immune Non-responders With HIV-1 Infection
NCT04297488
SHIFT: Studying HIV Immunology After Fecal Transplant
NCT03163784
Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection
NCT01838915
An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.
NCT03517631
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-Retroviral Agents
First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Antiretroviral therapy naive
* CD4 T cell counts\<350cells/mm3
* Agree to participate
Exclusion Criteria
* Cocurrent cancer or opportunistic infection
* Liver diseases
* received antibiotics within four weeks of enrollment
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Public Health Clinical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hongzhou Lu
Vice Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Mic-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.